Considerations for using newer, novel-based combination regimens to treat patients with metastatic colorectal cancer based on strategies explored in recent clinical trials.
EP. 1: Treatment Gaps for Patients With Metastatic CRC
Reactions to the increase in prevalence of metastatic colorectal cancer (CRC) among a younger patient population despite treatment advances.
EP. 2: Molecular Markers and Tumor Sidedness in Metastatic CRC
Metastatic colorectal cancer (CRC) experts discuss tumor sidedness and their current use of next-generation sequencing panels to assess patients and guide treatment decisions.
EP. 3: MSS Metastatic CRC: First-Line Treatment Selection
Tumor characteristics, patient factors, and supporting data that affect frontline treatment decisions for patients with microsatellite stable (MSS) metastatic colorectal cancer.
EP. 4: Metastatic CRC: Frontline Therapy With EGFR Inhibitors
Mayo Clinic’s Joleen M. Hubbard, MD, interprets data recently presented on the use of EGFR inhibitors as frontline therapy for appropriate patients with metastatic colorectal cancer.
EP. 5: MSI-H Metastatic CRC: Frontline Immunotherapy
Considerations for frontline immunotherapy for patients with microsatellite instability high metastatic colorectal cancer based on data from the KEYNOTE-177 and CheckMate 142 studies.
EP. 6: MSI-H Metastatic CRC: Chemo Vs I-O Debated
Drs. John L. Marshall, Marwan G. Fakih, and Joleen M. Hubbard, describe the current role of chemotherapy for frontline metastatic colorectal cancer based on novel treatment advances.
EP. 7: Metastatic CRC: Nivolumab Plus Regorafenib
Considerations for treating patients with metastatic colorectal cancer with the combination of nivolumab and regorafenib based on preliminary data.
EP. 8: Metastatic CRC: Pembrolizumab Plus Lenvatinib
Implications for using the combination of pembrolizumab and lenvatinib to treat patients with metastatic colorectal cancer based on updated data from the LEAP-005 study.
EP. 9: Treating Metastatic CRC With TKI/I-O Combinations
The rationale for continuing to study the combination of immunotherapies with novel tyrosine kinase inhibitors in metastatic colorectal cancer.
EP. 10: Novel Approaches Under Study for Metastatic CRC
John L. Marshall, MD; Marwan G. Fakih, MD; and Joleen M. Hubbard, MD, highlight novel strategies in the metastatic colorectal cancer pipeline that look exciting and consider their integration into future clinical practice.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512